Search - tctmd.com

Displaying 421 - 440 of 543

Sort: Relevancy | Date

News Daily News

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Michael O'Riordan

October 24, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Merck Calls Quits on CETP Inhibitor Anacetrapib

Michael O'Riordan

October 12, 2017

News Daily News

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

Todd Neale

September 22, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Yael L. Maxwell

September 06, 2017

News Conference News ESC 2017

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Michael O'Riordan

September 05, 2017

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

Presentation ESC 2017

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Presenter: Robert Giugliano

August 28, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Yael L. Maxwell

August 07, 2017

News Daily News

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

Michael O'Riordan

August 02, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

Advertisement

More CVD and Stroke Drive Shorter Life Spans in African-Americans: AHA

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Merck Calls Quits on CETP Inhibitor Anacetrapib

Secondary Prevention Lagging Behind in Women With Established Coronary Disease

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

ACC Updates Recommendations for Non-statin Therapy Use for LDL-Cholesterol Lowering in Secondary Prevention

Inclisiran Offers Sustained LDL-Lowering Through 1 Year: ORION-1

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Evolocumab Not Cost-Effective at Current List Price

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

ADAPT-DES at 2 Years Offers Insights Into Provider Strategies and Aspirin Monotherapy Beyond 1 Year

Many Stroke Patients Stop Statins or Never Start, With Dire Consequences

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content